Henrik Daub und Kinaxo - Info zur Person

(1 - 16 von 24

)

KINAXO Enters Agreement with AstraZeneca

www.b3cnewswire.com

Dr. Henrik Daub, CTO at KINAXO commented: “Posttranslational modifications and their regulation are key factors in understanding cellular behavior and molecular drug action. We are delighted to apply our expertise to ...

Bio M Newsletter Fokus München Neugründungen Kinaxo ...

db.bio-m.org

Dr. Axel Ullrich und Dr. Henrik Daub. Der Schwerpunkt der Aktivitäten liegt auf der Entwicklung von hochspezifischen Kinase-Inhibitoren, die sich durch ein ...

KINAXO Announces European Patent Granted for its Chemical Proteomics...

www.bionity.com

KINAXO Biotechnologies GmbH announced that the European Patent Office has granted a patent entitled “Proteome-wide quantification of small molecule binding to...

KINAXO Announces Agreement with Johnson & Johnson | More ...

pipelinereview.com

· KINAXO is a spin-off from the Max Planck Institute of Biochemistry in Martinsried, initiated by Prof. Dr. Axel Ullrich and Dr. Henrik Daub as well as Max Planck Innovation GmbH, the technology transfer center of the Max Planck Society. KINAXO offers a comprehensive chemical proteomics technology - known as KinaTorTM - to identify and characterize the biological interaction of small …

Kinaxo Biotechnologies | Tracxntracxn.com › Kinaxo Biotechnologies

tracxn.com

... a technology platform in collaboration with the leading Max Planck laboratories of Axel Ullrich, Henrik Daub and Matthias Mann. Kinaxo's services cater mainly ...

DFG - GEPRIS - Privatdozent Dr. Henrik Daub

gepris.dfg.de

Privatdozent Dr. Henrik Daub, Kinaxo Biotechnologies GmbH, Am Klopferspitz 19a, Planegg

KINAXO Launches Enhanced KinaTor(TM) Cellular Profiling Service,...

www.pressebox.com

· The technology was developed by Dr Henrik Daub and Professor Axel Ullrich of the Max Planck Institute of Biochemistry in Martinsried and has been exclusively licensed by its technology transfer organization Max Planck Innovation to KINAXO Biotechnologies. Commenting on the new service, Dr Klaus Godl KINAXO's …

KINAXO Announces European Patent Granted for its Chemical Proteomics...

www.pressebox.com

Evotec AG, KINAXO Biotechnologies GmbH announced today that the European Patent Office has granted a patent entitled

KINAXO Enters Agreement with AstraZeneca, Evotec AG, Press release -...

www.pressebox.com

Evotec AG, KINAXO Biotechnologies GmbH announced today that it has entered into a collaboration with AstraZeneca. Under the terms o…

Kinaxo contributes its quantitative phosphoproteomics platform to a...

www.pressebox.com

Evotec AG, Kinaxo Biotechnologies GmbH announced today that it was awarded a grant by the Bavarian Research Foundation (Bayerische…

KINAXO erweitert "KinaTor"-Profiling | Chemiereport

www.chemiereport.at

Die Technologie wurde von Henrik Daub und Axel Ullrich vom Max Planck Institut für Biochemie in Martinsried entwickelt und exklusiv an ...

Chemical proteomics application patent grantedwww.chromatographyonline.com › view › chemical...

www.chromatographyonline.com

· ... providing chemical proteomics solutions for research and development,” says Henrik Daub, KINAXO's CTO and main inventor of the patent.

KINAXO Biotechnologies Announces European Patent Granted for its...

www.biospace.com

KINAXO Biotechnologies Announces European Patent Granted for its Chemical Proteomics Applications - read this article along with other careers information,...